Doripenem Market

The global Doripenem market size was valued at US$ 234 million in 2024 and is projected to reach US$ 278 million by 2030, at a CAGR of 2.9% during the forecast period 2024-2030.

United States Doripenem market size was valued at US$ 76 million in 2024 and is projected to reach US$ 88 million by 2030, at a CAGR of 2.5% during the forecast period 2024-2030.

Carbapenem antibiotic used to treat serious bacterial infections.

Slow growth due to competition from other broad-spectrum antibiotics. Concerns over antibiotic resistance limiting widespread use. Ongoing research into new formulations and combinations to address resistance.

Report Overview
Doripenem is an ultra-broad-spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005 and is being marketed outside Japan by Johnson & Johnson. It is particularly active against Pseudomonas aeruginosa. The usual form is doripenem monohydrate.
Doripenem Market provides a deep insight into the global Doripenem market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Doripenem Market, Doripenem Market introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, Doripenem Market is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Doripenem market in any manner.
Global Doripenem Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company

• Janssen
• Shionogi
• Apotex

• 500 mg single-use vial
• 250 mg single-use vial

• Hospital
• Drug store

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Doripenem Market
• Overview of the regional outlook of the Doripenem Market: